Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 Next >
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Issues Letter to Stockholders
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Corporate Governance Enhancements
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.